MX374105B - Compuestos azatricíclicos como inhibidores de tirosinas quinasas (jak) y el uso de los mismos en el tratamiento de enfermedades autoinmunes, inflamatorias y alérgicas. - Google Patents

Compuestos azatricíclicos como inhibidores de tirosinas quinasas (jak) y el uso de los mismos en el tratamiento de enfermedades autoinmunes, inflamatorias y alérgicas.

Info

Publication number
MX374105B
MX374105B MX2016014823A MX2016014823A MX374105B MX 374105 B MX374105 B MX 374105B MX 2016014823 A MX2016014823 A MX 2016014823A MX 2016014823 A MX2016014823 A MX 2016014823A MX 374105 B MX374105 B MX 374105B
Authority
MX
Mexico
Prior art keywords
sup
treatment
jak
autoimmune
inflammatory
Prior art date
Application number
MX2016014823A
Other languages
English (en)
Other versions
MX2016014823A (es
Inventor
Akio Yamamoto
Keishi Hayashi
Shunsuke Iwamoto
Kazunori Kurihara
Masataka Minami
Takanori Nakamura
Keiji Takahashi
Takuya Nishimura
Toshihiko Kamiyama
Miyuki Uni
Tsuneo Watanabe
Original Assignee
Nissan Chemical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nissan Chemical Ind Ltd filed Critical Nissan Chemical Ind Ltd
Publication of MX2016014823A publication Critical patent/MX2016014823A/es
Publication of MX374105B publication Critical patent/MX374105B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Los compuestos tricíclicos novedosos que tienen actividades inhibidoras de JAK son útiles para la prevención, tratamiento o mejora de enfermedades autoinmunes, enfermedades inflamatorias y enfermedades alérgicas se proporcionan; compuesto tricíclico novedoso representado por la fórmula (I), la fórmula (II) o la fórmula (III) (ver Formulas) (en donde: cada uno de A1, A2 y A3 es un grupo ciclohexano-1,4-diilo o lo similar; cada uno de L1, L2 y L3 es un grupo metileno o lo similar; cada uno de X1 y X3 es O o NH; cada uno de R1 y R3 es un grupo ciano haloalquilo de C1-6 o lo similar; y R2 es un grupo aromático heterocíclico), un tautómero o sal farmacéuticamente aceptable del compuesto o un solvato del mismo.
MX2016014823A 2014-05-14 2015-05-11 Compuestos azatricíclicos como inhibidores de tirosinas quinasas (jak) y el uso de los mismos en el tratamiento de enfermedades autoinmunes, inflamatorias y alérgicas. MX374105B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014100712 2014-05-14
PCT/JP2015/063504 WO2015174376A1 (ja) 2014-05-14 2015-05-11 ３環性化合物及びｊａｋ阻害剤

Publications (2)

Publication Number Publication Date
MX2016014823A MX2016014823A (es) 2017-03-10
MX374105B true MX374105B (es) 2025-03-05

Family

ID=54479915

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016014823A MX374105B (es) 2014-05-14 2015-05-11 Compuestos azatricíclicos como inhibidores de tirosinas quinasas (jak) y el uso de los mismos en el tratamiento de enfermedades autoinmunes, inflamatorias y alérgicas.

Country Status (20)

Country Link
US (2) US9890165B2 (es)
EP (1) EP3144309B1 (es)
JP (1) JP6561984B2 (es)
KR (1) KR20170003521A (es)
CN (1) CN106459050B (es)
AU (1) AU2015260349B2 (es)
BR (1) BR112016023299A8 (es)
CA (1) CA2944433A1 (es)
ES (1) ES2744213T3 (es)
IL (1) IL248928B (es)
MX (1) MX374105B (es)
MY (1) MY182812A (es)
NZ (1) NZ725001A (es)
PH (1) PH12016501846A1 (es)
RU (1) RU2674262C2 (es)
SG (1) SG11201608542YA (es)
TW (1) TWI666210B (es)
UA (1) UA118876C2 (es)
WO (1) WO2015174376A1 (es)
ZA (1) ZA201607210B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
ES2922379T3 (es) 2016-12-16 2022-09-14 Janssen Pharmaceutica Nv Compuestos de imidazo[4,5,D]pirrolo[2,3,B]piridina como inhibidores de Janus quinasas
TW202016110A (zh) 2018-06-15 2020-05-01 比利時商健生藥品公司 Ｊａｋ激酶家族之小分子抑制劑
KR20210142154A (ko) 2019-03-21 2021-11-24 옹쎄오 암 치료를 위한 키나제 억제제와 조합된 dbait 분자
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2022155202A1 (en) * 2021-01-13 2022-07-21 Schrödinger, Inc. Fused heterocycles and uses of same
JP2024509587A (ja) 2021-03-11 2024-03-04 ヤンセン ファーマシューティカ エヌ．ベー． Ｊａｋ媒介性障害の治療に使用するためのｌｏｒｐｕｃｉｔｉｎｉｂ

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA72290C2 (uk) 1999-12-10 2005-02-15 Пфайзер Продактс Інк. СПОЛУКИ ПІРОЛО[2.3-d]ПІРИМІДИНУ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ (ВАРІАНТИ), СПОСІБ ІНГІБУВАННЯ ПРОТЕЇНКІНАЗ АБО JANUS КІНАЗИ 3 (ВАРІАНТИ)
EP2251341A1 (en) 2005-07-14 2010-11-17 Astellas Pharma Inc. Heterocyclic Janus kinase 3 inhibitors
EP1910358A2 (en) 2005-07-14 2008-04-16 Astellas Pharma Inc. Heterocyclic janus kinase 3 inhibitors
KR20090106604A (ko) 2007-01-12 2009-10-09 아스텔라스세이야쿠 가부시키가이샤 축합 피리딘 화합물
SI2299821T1 (sl) 2008-06-10 2016-03-31 Abbvie Inc. Triciklične spojine
AU2010237859A1 (en) 2009-04-14 2011-11-03 Astellas Pharma Inc. Fused pyrrolopyridine derivative
CA2776028C (en) 2009-10-15 2015-12-01 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine compounds
PL2506716T3 (pl) 2009-12-01 2017-10-31 Abbvie Inc Nowe związki tricykliczne
US8785639B2 (en) * 2009-12-01 2014-07-22 Abbvie Inc. Substituted dihydropyrazolo[3,4-D]pyrrolo[2,3-B]pyridines and methods of use thereof
ES2461967T3 (es) 2009-12-18 2014-05-21 Pfizer Inc. Compuestos de pirrolo[2,3-d]pirimidina
CN102712640A (zh) 2010-01-12 2012-10-03 弗·哈夫曼-拉罗切有限公司 三环杂环化合物、其组合物和应用方法
WO2012085176A1 (en) * 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Tricyclic pyrazinone compounds, compositions and methods of use thereof as janus kinase inhibitors
CA2830882C (en) 2011-03-22 2021-03-16 Dinesh Barawkar Substituted fused tricyclic compounds, compositions and medicinal applications thereof
WO2012149280A2 (en) 2011-04-29 2012-11-01 Abbott Laboratories Novel tricyclic compounds
BR112014002472A2 (pt) * 2011-08-12 2017-04-11 Nissan Chemical Ind Ltd "compostos heterocíclicos tricíclicos, seu uso, agente terapêutico para reumatismo articular e medicamento"
EP2955181B1 (en) 2013-02-08 2019-10-30 Nissan Chemical Corporation Tricyclic pyrrolopyridine compound, and jak inhibitor

Also Published As

Publication number Publication date
IL248928A0 (en) 2017-01-31
CN106459050B (zh) 2019-02-26
JPWO2015174376A1 (ja) 2017-04-20
MX2016014823A (es) 2017-03-10
BR112016023299A8 (pt) 2021-06-29
TW201607947A (zh) 2016-03-01
ES2744213T3 (es) 2020-02-24
AU2015260349B2 (en) 2019-02-21
HK1231468A1 (en) 2017-12-22
UA118876C2 (uk) 2019-03-25
US9890165B2 (en) 2018-02-13
KR20170003521A (ko) 2017-01-09
BR112016023299A2 (pt) 2017-08-15
SG11201608542YA (en) 2016-11-29
RU2016148866A3 (es) 2018-06-20
IL248928B (en) 2020-01-30
PH12016501846A1 (en) 2016-12-19
CA2944433A1 (en) 2015-11-19
NZ725001A (en) 2021-08-27
US20180099966A1 (en) 2018-04-12
MY182812A (en) 2021-02-05
RU2016148866A (ru) 2018-06-20
TWI666210B (zh) 2019-07-21
JP6561984B2 (ja) 2019-08-21
EP3144309A1 (en) 2017-03-22
WO2015174376A1 (ja) 2015-11-19
AU2015260349A1 (en) 2016-10-06
CN106459050A (zh) 2017-02-22
EP3144309A4 (en) 2017-09-20
EP3144309B1 (en) 2019-08-14
US20170044161A1 (en) 2017-02-16
RU2674262C2 (ru) 2018-12-06
US10385052B2 (en) 2019-08-20
ZA201607210B (en) 2018-05-30

Similar Documents

Publication Publication Date Title
MX374105B (es) Compuestos azatricíclicos como inhibidores de tirosinas quinasas (jak) y el uso de los mismos en el tratamiento de enfermedades autoinmunes, inflamatorias y alérgicas.
CY1124800T1 (el) Παραγωγο πυριδο[3,4-d]πυριμιδινης και φαρμακευτικως αποδεκτο αλας αυτου
CL2019002032A1 (es) Procesos para preparar un inhibidor de jak1 (divisional de solicitud 1790-2018).
CU20210015A7 (es) COMPUESTOS DE PIRAZOLO [3.4-b] PIRIDINA COMO INHIBIDORES DE CINASAS TAM Y MET
EA201592199A1 (ru) Производные бипиразола в качестве ингибиторов jak
UY36244A (es) Derivados de la pirimidinona como inhibidores del factor xia y/o de la calicreína plasmática y composiciones farmacéuticas que los contienen
MX2020012520A (es) Macrociclos con grupos p2' heterociclicos como inhibidores del factor xia.
CR20160523A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
MX388140B (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret.
PH12016502252A1 (en) Addition salts of (s)-2-(1-(6-amino-5-cyanopyrimidin-4-ylamino)ethyl)-4-oxo-3-phenyl-3,4-dihydropyrrolo[1,2-f][1,2,4]triazine-5-carbonitrile
PH12015501934B1 (en) New octahydro - pyrrolo [3,4-c] - pyrrole derivatives and analogs thereof as autotaxin inhibitors
CO2018011408A2 (es) Compuestos de pirimidina como inhibidores de la quinasa jak
EA201691625A1 (ru) Ароматические гетероциклические соединения как противовоспалительные соединения
EA201791274A1 (ru) ЗАМЕЩЕННЫЕ ПИПЕРИДИНОМ ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНА С ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ РЕПЛИКАЦИИ РЕСПИРАТОРНО-СИНЦИТИАЛЬНОГО ВИРУСА (RSV)
MX382261B (es) Derivados heterociclicos y uso de los mismos.
MX388321B (es) Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.
AR102981A1 (es) Inhibidores de la necrosis celular y métodos de preparación de los mismos
MX2022007436A (es) Inhibidores de la autotaxina y sus usos.
MX2018001992A (es) Compuestos triciclicos heterociclicos como inhibidores de fosfoinositol 3-quinasa.
EA201790016A1 (ru) АНАЛОГ ПИРИДИНО[1,2-a]ПИРИМИДОНА, ПРИМЕНЯЕМЫЙ В КАЧЕСТВЕ ИНГИБИТОРА PI3K
SA519401827B1 (ar) [3، 4- d] مشتق بيريدو بيريميدين وملح مقبول صيدلانياً منه
MX379437B (es) Derivados de hidrazina-bencilo sustituidos, como inhibidores de ppp1r15a y ppp1r15b, y el uso de los mismos para el tratamiento de trastorno de proteostasis.
EA201791743A1 (ru) Производные имидазо[2,1-в]тиазола и 5,6-дигидроимидазо[2,1-в]тиазола, применяемые в качестве s100-ингибиторов
MX381425B (es) Compuestos heterociclicos biciclicos sustituidos.
DOP2015000299A (es) Derivados de prodroga de triazolpiridinas sustituidas

Legal Events

Date Code Title Description
FG Grant or registration